## FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV485023544US Express Mail Label Number SEPTEMBER 8, 2004 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 0/506936

IN RE PCT NATIONAL STAGE APPLICATION OF

NAKAJIMA ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/02365

FILED: 7 MARCH 2003

U.S. APPLICATION NO: Not Yet Assigned

35 USC §371 DATE:

FOR: MATRIX METALLOPROTEINASE INHIBITORS IN COMBINATION WITH

HYPOTHERMIA AND/OR RADIOTHERAPY FOR THE TREATMENT OF

CANCER

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/02365, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080

(862) 778-7960

Date: September 8, 2004

Respectfully submitted,

Edward J) Wilusz, Jr. Attokney for Applicants

Reg. No. 52,370

FORM PTO-1449
(REV. 7-85)
U.S. DEPARTMENT OF COMMERCE PATENT OF RADEMARK OFFICE INFORMATION DISCLOSSEE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILII	NG DATE	
	AA								
	AB					_			
	AC								
	AD								
	AE								
	AF								
	AG								
	АН								
	Al								
	AJ								
	AK								
	AL								
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO		
	AM	WO 98 07697	2/26/98	WIPO					
	AN	WO 00 38717	7/6/00	WIPO					
	AO	WO 99 21583	5/6/99	WIPO					
	AP								
	AQ								
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)									
	AR	M. Haq et al., "Addition of Matrix Metalloproteinase Inhibition to Coventional Cytotoxic Therapy Reduces Tumor Implantation and Prolongs Survival in a Murline Model of Human Pancreatic Cancer", Cancer Research, Vol. 60, No. 12, pp 3207-3211							
	AS	A.L. Thomas et al., "Marimastat: The Clinical Developmetn of a Matrix Metalloproteinase Inhibitor", Expert Opinion on Investigational Drugs, Vol. 9, No. 12, pp. 2913-2922, (2000)							
	АТ	L. Jones et al., "The Matrix Metalloproteinases and their Inhibitors in the Treatment of Pancreatic Cancer", Animals of the New York Acendmy of Sciences, Vol. 880, pp. 288-307, (1999)							
FYAMIN	<u> </u>	•		DATE CONSIDERED					

<sup>\*</sup>EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)
U.S. DEPAREMENT OF COMMERCE PATENT TRADEMARK OFFICE INFORMATION DISCLOSORE CITATION

(Use several sheets if necessary)

sheet 2012 506936

ATTY-DOCKE
PCA-300-APPLICATION
Not Yet Assigned
APPLICANT
NAKAJIMA ET AL.

**FILING DATE** 

Group

EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)					
	DA	Yasunobu Sawaji et al., "Transient Increase of Intracellular cAMP by Heat Shock Initiates the Suppression of MT1-MMP Production of Tumor Cells" Animals of the New York Academy of Sciences, Vol. 878, pp. 707-709, (1999)				
	DB					
	DC					
	DD					
	DE					
	DF					
	DG					
	DH					
	DI					
	DJ					
	DK					
	DL					
	DM					
	DN					
EXAMINE	R	DATE CONSIDERED				

<sup>\*</sup>EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.